Opus Genetics (IRD) Reiterated at Market Outperform by Citizens Ahead of Phase 1/2 BIRD-1 Trial

August 19, 2026 4:31 AM

Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $12.00 price target on Opus Genetics (NASDAQ: IRD).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found